注册 | 登录 | 充值

首页-> 学术资讯 -> 临床医学

人人看懂PD-1:6大癌种一线数据(2022.1.26)

临床医学

2022-01-28      

1572 0

截至2022.1.26,更新了目前获批的各类PD-1/PD-L1一线治疗数据,囊括非小细胞肺癌(非鳞、鳞癌)、小细胞肺癌、肝癌、食管癌、鼻咽癌。

非小细胞肺癌新更新了舒格利单抗数据,小细胞肺癌附上斯鲁利单抗数据(大概率未来获批)。

PFS数据完全,一部分OS数据均为达到,以NR显示,待后续更新,胃癌一线目前仅O药,暂不绘图比较。

参考文献:(上下滑动查看更多)

[1] Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021 Aug 28;398(10302):759-771.

[2] Luo  H, Lu  J, Bai  Y,  et al.  Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial.   JAMA. Published online September 14, 2021.

[3] DaSilva LL, Aguiar PN, de Lima Lopes G. Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge. JAMA Oncol. 2021;7(11):1613–1614.

[4] Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology, 2021 Aug; 22(8): 1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23. PMID: 34174189.

[5] Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature Medicine, 2021 Sep; 27(9): 1536-1543. doi: 10.1038/s41591-021-01444-0. Epub 2021 Aug 2. PMID: 34341578.

[6] 2021 ASCO LAB 2.

[7] Cheng A L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021 Dec 10:S0168-8278(21)02241-8.

[8] CT009 - IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

[9] Qin S K, Ren Z G, Feng Y X, et al. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer. 2021 Jul;10(4):296-308.

[10] Finn RS, Qin S, Ikeda M, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). 2021ASCO GI,abs267.

[11] Ren Z G, Xu J M, Bai Y X, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. The Lancet Oncology. 2021, 22(7): 977-990.

[12]Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al. Durvalumab,with or without tremelimumab,plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.The Lancet Oncology.2020.

[13]Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia.2019 ESMO ASIA.

[14]Jonathan W G , Marina C G, Yuanbin Chen,et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 Nov;149:46-52.

[15]https://mp.weixin.qq.com/s/8eiE_5-f_1R658cuhw_z5Q


科研加油站:

为提高我国临床医护人员科研水平与科研能力,鼓励基于循证的血糖监测相关的临床医学研究及实践,北京康盟慈善基金会发起并设立了“盟动医研社”平台,以“科研浩海,盟动助力”为主题,计划推出十场科研技能培训系列主题的线上课程,只要分为真实世界研究临床科研技能提升数据统计及文章发表等三个方向供大家学习。



科研资讯(站内):

百度浏览   来源 : VIP说   


版权声明:本网站所有注明来源“医微客”的文字、图片和音视频资料,版权均属于医微客所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源:”医微客”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,转载仅作观点分享,版权归原作者所有。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。 本站拥有对此声明的最终解释权。

科研搜索(百度):医学科研





发表评论

注册或登后即可发表评论

登录注册

全部评论(0)

没有更多评论了哦~

科研资讯 更多>>
  • 一文解锁 | 如何在医微客参与市..
  • 顶级三甲华西医院政策:发论文只..
  • 循环肿瘤细胞检测在胃肠道肿瘤诊..
  • 卫健委最新发布:该项考核不合格..
  • 推荐阅读 更多>>
  • 饶毅:中国脑计划是我见过的最差..
  • 北京新增9例感染者!新增2个中风..
  • “人体胎盘”交易曝光,价格不菲..
  • 游戏干预对青少年抑郁和焦虑的有..